OLUX
Clinical safety rating: caution
Comprehensive clinical and safety monograph for OLUX (OLUX).
Corticosteroid with anti-inflammatory, antipruritic, and vasoconstrictive properties. Binds to glucocorticoid receptors, modulating gene expression to inhibit phospholipase A2, reducing prostaglandin and leukotriene synthesis.
| Metabolism | Topical administration; minimal systemic absorption. Absorbed fraction is metabolized in the liver via CYP3A4. |
| Excretion | Primarily hepatic metabolism with renal excretion of metabolites; less than 1% of the applied dose is excreted unchanged in urine. In fecal elimination, approximately 0.5-2% is recovered after topical application. |
| Half-life | The terminal elimination half-life is approximately 3 hours for clobetasol propionate following topical application. This short half-life supports once- to twice-daily dosing for efficacy while minimizing systemic accumulation. |
| Protein binding | Clobetasol propionate is approximately 96-98% bound to plasma proteins, predominantly albumin and corticosteroid-binding globulin (CBG). |
| Volume of Distribution | The apparent volume of distribution (Vd/F) for clobetasol propionate after topical application is difficult to determine accurately due to limited systemic absorption. In systemic studies with intravenous administration, Vd is estimated to be 1-2 L/kg, indicating extensive tissue distribution. After topical application, the Vd is not clinically meaningful due to negligible systemic levels. |
| Bioavailability | Bioavailability after topical application is less than 1% of the applied dose; systemic absorption is minimal and dependent on skin integrity, vehicle, and site of application. Oral bioavailability is negligible due to extensive first-pass metabolism. The product is intended for topical use only. |
| Onset of Action | Onset of action for OLUX (clobetasol propionate) foam is rapid; clinical improvement (reduction in erythema, scaling, and pruritus) is typically observed within 1 week of twice-daily application. For the ointment and cream formulations, onset is also within several days to 1 week. |
| Duration of Action | Duration of action after a single application is approximately 12-24 hours, consistent with twice-daily dosing recommendations. With continued use, clinical effects are maintained; prolonged use (beyond 2 weeks) is discouraged due to risk of local and systemic adverse effects. |
Olux (clobetasol propionate) is a topical corticosteroid. Apply a thin layer to affected skin areas twice daily. Maximum adult dose: 50 g (or 50 mL) per week. Treatment duration should not exceed 2 consecutive weeks. Not for use on face, groin, or axillae.
| Dosage form | AEROSOL, FOAM |
| Renal impairment | No dosage adjustment required for renal impairment as systemic absorption is minimal. |
| Liver impairment | No dosage adjustment required for hepatic impairment as systemic absorption is minimal. |
| Pediatric use | Safety and efficacy in pediatric patients have not been established; use is not recommended due to potential for significant systemic absorption and adrenal suppression. For children aged 12 years and older, apply a thin layer to affected area once or twice daily for up to 2 weeks; maximum dose: 25 g per week. |
| Geriatric use | No specific dose adjustment in elderly. Use with caution due to increased risk of skin atrophy and systemic effects; apply the shortest duration and smallest amount necessary. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for OLUX (OLUX).
| Breastfeeding | Excretion into breast milk is unknown for topical clobetasol propionate. Systemic absorption is minimal with proper use (about 1-5%). M/P ratio not established. Use on smallest area for shortest duration; avoid application to nipples or breast area to prevent infant exposure. Caution recommended. |
| Teratogenic Risk | Pregnancy category C. Topical corticosteroids have been associated with fetal growth restriction and adrenal suppression when used systemically. First trimester: limited data, theoretical risk of cleft palate with prolonged use. Second/third trimesters: risk of intrauterine growth restriction (IUGR) and low birth weight with extensive or prolonged use. Avoid use in large amounts or occluded areas. Use lowest effective dose for shortest duration. |
■ FDA Black Box Warning
None
| Serious Effects |
["Hypersensitivity to clobetasol propionate or any component of the formulation","Viral or fungal infections of the skin","Untreated bacterial infections"]
| Precautions | ["Systemic absorption may cause reversible hypothalamic-pituitary-adrenal (HPA) axis suppression","Local adverse reactions including skin atrophy, striae, telangiectasias, and acneiform eruptions","Avoid use on face, groin, or axillae due to increased risk of atrophy","Do not use with occlusive dressings unless directed","Pediatric patients may be more susceptible to systemic toxicity"] |
Loading safety data…
| Fetal Monitoring | Monitor fetal growth via ultrasound if prolonged use or large body surface area (>10%) to assess for IUGR. Assess maternal adrenal function if signs of Cushing syndrome. Monitor infant for adrenal suppression if maternal use was extensive near term. |
| Fertility Effects | No specific data on human fertility effects. Animal studies show no impairment of fertility with topical corticosteroids at therapeutic doses. Unlikely to affect fertility due to minimal systemic absorption. |